Management of osteoporosis in liver disease

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 6-7, 2011, Pages 438-445

  Guañabens, Núria ^a   Parés, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BILE ACID; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; COLLAGEN; COLLAGEN TYPE 1 ALPHA1 SP1; CORTICOSTEROID; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; FIBRONECTIN; FLUORIDE SODIUM; GLUCOCORTICOID; IBANDRONIC ACID; LITHOCHOLIC ACID; OSTEOCALCIN; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISONE; PROTEIN P55; RALOXIFENE; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ALCOHOL CONSUMPTION; ARTIFACT; ASCITES; AUTOIMMUNE HEPATITIS; BODY MASS; BONE DENSITOMETRY; BONE DESTRUCTION; BONE TURNOVER; CHOLESTASIS; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; EARLY MENOPAUSE; ESOPHAGITIS; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL ABSORPTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEMOCHROMATOSIS; HORMONAL THERAPY; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOGONADISM; JAUNDICE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARACENTESIS; PATHOGENESIS; PATIENT COMPLIANCE; PHLEBOTOMY; POSTMENOPAUSE; PRIMARY BILIARY CIRRHOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; RISK REDUCTION; SECONDARY AMENORRHEA; SEX DIFFERENCE; SHORT SURVEY; SIDE EFFECT; SMOKING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 80052324278     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.03.007     Document Type: Short Survey

References (53)

1. Compston JE. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut 1986;27:1073-90.
2. Pares A, Guanabens N. Treatment of bone disorders in liver disease. J Hepatol 2006;45:445-53.
3. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
4. Guanabens N, Pares A. Liver and bone. Arch Biochem Biophys 2010;503:84-94.
5. Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990;31:82-7.
6. Olsson R, Johansson C, Lindstedt G, Mellstrom D. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 1994;29:753-6.
7. Guanabens N, Cerda D, Monegal A, Pons F, Caballeria L, Peris P, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010;138:2348-56.
8. Guanabens N, Monegal A. Bone disease after liver transplantation. In: Compston J, Shane E. Boston: Elsevier; 2005. p. 271-85.
9. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001;12:484-92.
10. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001;357:342-7.
11. Navasa M, Monegal A, Guanabens N, Peris P, Rimola A, Munoz-Gomez J, et al. Bone fractures in liver transplant patients. Br J Rheumatol 1994;33:52-5.
12. Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003;9:321-30.
13. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987;7:137-42.
14. Guanabens N, Pares A, Marinoso L, Brancos MA, Piera C, Serrano S, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990;85:1356-62.
15. Guanabens N, Pares A, Alvarez L, Martinez de Osaba MJ, Monegal A, Peris P, et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998;13:731-8.
16. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998;28:695-9.
17. Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998;28:122-31.
18. Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res 2008;23:1278-86.
19. Ruiz-Gaspa S, Guanabens N, Enjuanes A, Peris P, Martinez-Ferrer A, de Osaba MJ, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010;40:25-34.
20. Cuthbert JA, Pak CY, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984;4:1-8.
21. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993;14:819-27.
22. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 1994;12:223-31.
23. Guanabens N, Enjuanes A, Alvarez L, Peris P, Caballeria L, Jesus Martinez de OM, et al. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J Bone Miner Metab 2009;27:347-54.
24. Nakchbandi IA, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 2009;6:660-70.
25. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004;89:4325-30.
26. Guggenbuhl P, Deugnier Y, Boisdet JF, Rolland Y, Perdriger A, Pawlotsky Y, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005;16:1809-14.
27. Diamond T, Stiel D, Lunzer M, Wilkinson M, Posen S, Ethanol reduces bone formation, et al. Med 1989;86:282-8.
28. Peris P, Pares A, Guanabens N, Pons F, Martinez de Osaba MJ, Caballeria J, et al. Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol 1992;27:619-25.
29. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989;110:430-6.
30. Pares A, Guanabens N, Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005;17:311-5.
31. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941-66.
32. Martinez-Ferrer A, Reyes R, Monegal A, Muxi A, Caballeria J, Peris P, et al. Patients with ascites have false values of bone mineral density at the central skeleton. A prospective study. J Hepatol 2010;52:S331.
33. Guanabens N, Pares A, Monegal A, Peris P, Pons F, Alvarez L, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997;113:219-24.
34. Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997;26:325-30.
35. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000;33:878-82.
36. Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98:2268-74.
37. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42:762-71.
38. Guanabens N, Vazquez I, Alvarez L, Pons F, Caballeria L, Cerda D, et al. Alendronate 70 mg once-weekly is more effective and has a better tolerability than alendronate 10 mg daily in the treatment of osteopenia aassociated with primary biliary cirrhosis. JBMR 2005;20:S279.
39. Guanabens N, Cerda D, Monegal A, Muxi A, Caballeria L, Peris P, et al. Monthly ibandronate vs. weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis: Similar efficacy but different adherence. J Hepatol 2010;52:S79.
40. Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver trans plantation: a prospective single-center study. Liver Transpl 2005;11:960-6.
41. Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int 2006;17:942-9.
42. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 2002;37:93-100.
43. Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 2003;14:82-9.
44. Monegal A, Guanabens N, Suarez MJ, Suarez F, Clemente G, Garcia-Gonzalez M, et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009;22:198-206.
45. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006;144:239-48.
46. Misof BM, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, et al. Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int 2008;83:167-75.
47. Diamond T, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991;6:39-43.
48. Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D'Angelo A, et al. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997;24:239-44.
49. Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994;20:633-7.
50. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995;57:15-9.
51. Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001;34:292-8.
52. Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005;25:117-21.
53. Dresner-Pollak R, Gabet Y, Steimatzky A, Hamdani G, Bab I, Ackerman Z, et al. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology 2008;134:259-67.